ResoTher Pharma A/S: Financial statements 2022
CVR: 37852406
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
ResoTher Pharma A/S (CVR 37852406) has filed annual accounts for 2022. In 2022, the company reported a net result of DKK -27,218,000 compared with DKK -11,678,000 the year before. Equity in the 2022 report amounted to DKK 12,174,000. The solvency ratio was 68,370.2%. The company had 3 employees in the financial year.
- Profit/Loss
- DKK -27,218,000
- Equity
- DKK 12,174,000
- Total Assets
- DKK 17,806
- Employees
- 3
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | - | -27.2M | 12.2M | 3 |
| 2021 | - | - | -11.7M | 38.6M | 3 |
| 2020 | - | - | -5.2M | -560K | 2 |
| 2019 | - | - | -3.9M | 1.7M | - |
| 2018 | - | -2.1M | -2.4M | -1.5M | 1 |
Official annual report
Keep an eye on ResoTher Pharma A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
ResoTher Pharma A/S has published its annual report for 2021. The net result was DKK -11,678,000.
On May 18, 2022, the company changed its name from ResoTher Pharma ApS to ResoTher Pharma A/S.
About ResoTher Pharma A/S
ResoTher Pharma A/S is a Danish company of the type Aktieselskab based in Holte, founded in 2016. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named ResoTher Pharma ApS. The management consists of Anders Kronborg. The board consists of Rebecca Anne Morison (chair), Henrik Stage, Jeppe Øvli Øvlesen and Michael Østerlund Madsen. The company is owned by Quantass ApS and TJ Biotech Holding ApS. The company has 4 employees (2026). Equity in the 2025 report amounted to DKK 12,132,000.